Secondary outcomes: progression/regression of mRSS and decline/increase of FVC
| mRSS | FVC | |||
| Progression | Regression | Decline | Increase | |
| Estimated treatment effect of TCZ with OR (95% CI) | 0.7 (0.1 to 4.8) | 1.1 (0.4 to 2.7) | 0.8 (0.3 to 2.2) | 1.5 (0.6 to 3.8) |
| P values | 0.74 | 0.86 | 0.63 | 0.41 |
These results represent our main analysis with a nearest neighbour matching algorithm and selection of most recent observation in control patients with multiple possible baseline observations.
CI, confidence interval; FVC, forced vital capacity; mRSS, modified Rodnan skin score; OR, odds ratio; TCZ, tocilizumab.